Twist Bioscience Corporation (TWST)
NASDAQ: TWST · Real-Time Price · USD
118.00
-0.57 (-0.48%)
Aug 17, 2026, 9:30 AM EDT - Market open
Twist Bioscience Revenue
Twist Bioscience had revenue of $118.38M in the quarter ending June 30, 2026, with 23.24% growth. This brings the company's revenue in the last twelve months to $431.80M, up 19.19% year-over-year. In the fiscal year ending September 30, 2025, Twist Bioscience had annual revenue of $376.57M with 20.32% growth.
Revenue (ttm)
$431.80M
Revenue Growth
+19.19%
P/S Ratio
17.22
Revenue / Employee
$441,060
Employees
979
Market Cap
7.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 376.57M | 63.60M | 20.32% |
| Sep 30, 2024 | 312.97M | 67.87M | 27.69% |
| Sep 30, 2023 | 245.11M | 41.54M | 20.41% |
| Sep 30, 2022 | 203.57M | 71.23M | 53.83% |
| Sep 30, 2021 | 132.33M | 42.23M | 46.87% |
| Sep 30, 2020 | 90.10M | 35.72M | 65.67% |
| Sep 30, 2019 | 54.39M | 28.96M | 113.89% |
| Sep 30, 2018 | 25.43M | 14.66M | 136.16% |
| Sep 30, 2017 | 10.77M | 8.50M | 374.53% |
| Sep 30, 2016 | 2.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.29B |
| Charles River Laboratories International | 4.00B |
| Revvity | 2.91B |
| Medpace Holdings | 2.78B |
| RadNet | 2.27B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.22B |
| Veracyte | 561.90M |
TWST News
- 12 days ago - Twist Bioscience price target raised to $115 from $85 at Piper Sandler - TheFly
- 12 days ago - Twist Bioscience 3.125M share Spot Secondary priced at $96.00 - TheFly
- 12 days ago - Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock - Business Wire
- 12 days ago - Twist Bioscience announces $250M common stock offering - TheFly
- 12 days ago - Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock - Business Wire
- 13 days ago - Twist Bioscience announces inducement grants under Nasdaq listing rule - TheFly
- 13 days ago - Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Twist Bioscience price target raised to $115 from $113 at Baird - TheFly